Laval, Canada
Laval, Canada

Time filter

Source Type

NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Engaged Capital, LLC (together with its affiliates, “Engaged Capital” or “we”), an investment firm specializing in enhancing the value of small and mid-cap North American equities with a 20.5% economic exposure to Rent-A-Center, Inc. (“RCII” or the “Company”) (NASDAQ:RCII), is compelled to remind stockholders of the facts following RCII’s recent letters to stockholders which obfuscate the truth of RCII’s corporate governance and make misleading statements about Engaged Capital’s highly qualified nominees. Reminder #1: The incumbent Board has destroyed significant stockholder value. Are the shareholder returns below1 indicative of incumbent directors that have proven themselves capable of delivering long-term stockholder value? Reminder #2: A primary cause of RCII’s poor performance is poor corporate governance. All three incumbent directors up for election at the 2017 Annual Meeting have been on the Board for the above periods of stockholder value destruction and have served on the Finance Committee, with responsibility for RCII’s key shortcomings, such as financial policies, capital structure, operating plans, and critical growth initiatives. The Board is long tenured, with five of seven directors serving on the Board for over ten years and two directors serving for over twenty years. A poor corporate governance structure led to failed succession planning and failed oversight. Furthermore, in response to Engaged Capital’s campaign for Board change, the incumbent directors have used the Company’s corporate machinery to disenfranchise stockholders and challenged Engaged Capital’s nominees on multiple grounds, amounting to what we consider a thinly veiled attempt to perpetuate the status quo. The Board has approved a three-year plan to turn the business around from its own self-admitted mistakes. Progress to date since Mark Speese returned as CEO is indicative of the challenge ahead. Core U.S. same store sales were negative 12.5% in Q1 2017 and negative 13.0% in April 2017. RCII is attempting this turnaround as its sole strategy while breaching debt covenants and requiring a waiver that restricts outstanding borrowings and that may restrict the dividend, which was already cut by 67% in 2016. Please see accompanying graphics 1, 2 and 3. Reminder #4: We offer an alternative. Engaged Capital is campaigning for stockholder friendly corporate governance and a commitment to openly and fairly evaluate ALL opportunities to enhance stockholder value to find the best path forward for ALL stockholders. Engaged Capital has simply requested that the Board objectively evaluate ALL strategic alternatives available to the Company before blindly embarking on a public turnaround plan. The Board has consistently refused our request. The Board also denied our request to seek stockholder approval to declassify the Board in 2018 as the incumbent directors are apparently fearful at the prospect of facing a stockholder vote on re-election every year. Our campaign is about ensuring that the RCII Board does what it was elected to do – represent the best interests of stockholders by acting as our fiduciaries. Given RCII’s significant underperformance under the incumbent Board’s watch, this MUST include evaluating all opportunities for creating stockholder value. ENGAGED CAPITAL HAS NOMINATED HIGHLY QUALIFIED, INDEPENDENT NOMINEES WITH STRONG TRACK RECORDS OF VALUE CREATION VOTE THE BLUE ENGAGED CAPITAL PROXY CARD FOR ALL THREE ENGAGED CAPITAL NOMINEES TODAY If you have any questions, or require assistance with your vote, please contact Saratoga Proxy Consulting LLC, toll- free at (888) 368-0379, call direct at (212) 257-1311 or email: info@saratogaproxy.com Engaged Capital, LLC (“Engaged Capital”) was established in 2012 by a group of professionals with significant experience in activist investing in North America and was seeded by Grosvenor Capital Management, L.P., one of the oldest and largest global alternative investment managers. Engaged Capital is a limited liability company owned by its principals and formed to create long-term shareholder value by bringing an owner’s perspective to the managements and boards of undervalued public companies. Engaged Capital’s efforts and resources are dedicated to a single investment style, “Constructive Activism” with a focus on delivering superior, long-term, risk-adjusted returns for investors. Engaged Capital is based in Newport Beach, California. 1 FactSet data as of 1/27/2017, the day before Engaged Capital 13D filing. 2 Source: RCII SEC filings. 3 Reported on a non-GAAP basis. 2017 EBITDA based on consensus estimates. Source: RCII SEC filings and FactSet. 4 2013 to 2016 net debt to EBITDA shown on LTM and non-GAAP basis.  NTM EBITDA per consensus estimates. Source: RCII SEC filings and FactSet. 5 From day before Mr. Brown was elected to the Medifast board to May 16, 2017. 6 From day before Mr. Brown was appointed to the Nordion board to date of transaction close. 7 Outerwall press release, July 25, 2016. 8 RCII total shareholder return from July 2000 to August 2015. Mr. Fadel was President and COO since July 2000 and December 2002, respectively, to August 2015 and a director from December 2000 to November 2013. 9 From day before effective date of Mr. Fadel’s resignation to 1/27/2017, the day before Engaged Capital 13D filing. All data per FactSet.


News Article | May 16, 2017
Site: www.prweb.com

Clinical Supplies Management (“CSM”), a Great Point Partners II (“GPP”) portfolio company, today announced two new executive appointments as the company continues to grow. CSM has doubled in size over the past six months with the acquisition of businesses in Belgium and Germany and is executing an aggressive growth strategy. Roger Gasper joins CSM as Chief Financial Officer. Roger has over 25 years of experience in finance and was most recently Chief Financial Officer of the JG Wentworth Company, a publicly held, diversified financial services company with over $4 Billion in assets. Previously, Roger spent several years in the life science industry at Ricerca, Nordion and MDS Pharma Services and started his career at Ernst & Young. Roger will be responsible for global finance and treasury functions and joins the executive leadership team. Scott Houlton, Chief Executive Officer commented, “I welcome Roger to the CSM team and look forward to working with him as we increase our scale and capability to support our global operations. Roger has great experience in both private and public companies and has extensive international experience that will instantly add value to CSM.” CSM also named David Fontaine as Vice President, Sales and Marketing. David was most recently Chief Business Development Officer at B&C Group prior to being acquired by CSM. David has nearly 20 years of experience with a strong background in growing businesses and was instrumental in establishing the business development function at B&C Group. He has broad industry experience including business development positions at GSK, Crucell and Dynavax. David will also join the executive leadership team and have responsibility for sales and marketing globally for CSM. “I am pleased to have David take on global responsibility in this new role. David has established robust business development processes and has been actively leading the integration of sales and marketing across CSM. Our sales and marketing group has grown rapidly over the past several months and I am excited with the progress already seen in attracting new customers to CSM,” said Scott Houlton. About Clinical Supplies Management Since 1997, CSM has been providing innovative solutions to meet the complex clinical supply challenges pharmaceutical and biotechnology companies face. CSM manages the clinical supply chain for hundreds of satisfied clients worldwide, providing services that keep clinical trials on time and on budget. CSM offers a full suite of cGMP-compliant services, continually delivering quality supplies to clinical sites and patients around the world. From Phase I all the way to large Phase III and IV projects, CSM has the flexibility to meet the needs of all drug trials regardless of size and scope. CSM’s customer-centric approach, revolutionary processes and state-of-the-art clinical services increase efficiencies, reduce costs and improve outcomes for clinical trials.


— According to Stratistics MRC, the Global Nuclear Medicine Market is valued at $4.42 billion in 2015 and is expected to grow at a CAGR of 10.55 % to reach $8.92 billion by 2022. Rising demand from emerging nations and the growing incidence of cardiovascular ailments and cancers are some of the key factors driving the market growth. Conversely, strict government regulations and competition from conventional diagnostic methods are hampering the market. Furthermore, technological advancements in neurological applications are anticipated to create ample of opportunities for the market in the future. North America is the largest market in terms of revenue in 2015 due to several technological advancements within the region. However, Asia Pacific is poised to grow at a faster pace due to the increasing incidence of neurological and cardiovascular diseases and cancer. Various new products are being launched together with the several technological advancements. Thus, new product launch is the key strategy followed by the players to gain the traction in the market. Some of the key players in global Nuclear Medicine market are Advanced Accelerator Applications S.A., Ashby Gorman Baker Ltd, Bayer Healthcare, Bracco Imaging S.P.A, Cardinal Health, Digirad, Eczcibasi-Monrol Nuclear Products, GE Healthcare, IBA Molecular Imaging, Lantheus Medical Imaging, Mallinckrodt PLC, Mediso Ltd., Nordion, Inc., Philips Healthcare and Siemens Healthcare. Regions Covered: North America US Canada Mexico Europe Germany France Italy UK Spain Rest of Europe Asia Pacific Japan China India Australia New Zealand Rest of Asia Pacific Rest of the World Middle East Brazil Argentina South Africa Egypt What our report offers: - Market share assessments for the regional and country level segments - Market share analysis of the top industry players - Strategic recommendations for the new entrants - Market forecasts for a minimum of 7 years of all the mentioned segments, sub segments and the regional markets - Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations) - Strategic recommendations in key business segments based on the market estimations - Competitive landscaping mapping the key common trends - Company profiling with detailed strategies, financials, and recent developments - Supply chain trends mapping the latest technological advancements About Us: Orbis Research (orbisresearch.com) is a single point aid for all your market research requirements. We have vast database of reports from the leading publishers and authors across the globe. We specialize in delivering customized reports as per the requirements of our clients. We have complete information about our publishers and hence are sure about the accuracy of the industries and verticals of their specialization. This helps our clients to map their needs and we produce the perfect required market research study for our clients. For more information, please visit http://www.orbisresearch.com/reports/index/nuclear-medicine-global-market-outlook-2015-2022


— Radiotherapy which is also known as RT or XTR is the procedure where in X-Rays are used to treat diseases like cancer. Radio therapy destroys cancer cells by damaging the DNA within the targeted area. As a result other cells are damaged but they are good in recover when compared to cancer cells. Study Objectives of Radiotherapy Market: • To provide detailed analysis of the market structure along with forecast for the next 10 years of the various segments and sub-segments of the Radiotherapy market • To provide insights about factors affecting the market growth • To analyze the Radiotherapy market based on various factors- price analysis, supply chain analysis, porters five force analysis etc. • To provide historical and forecast revenue of the market segments and sub-segments with respect to four main geographies and their countries- Americas, Europe, Asia-Pacific, and Middle East & Africa. • To provide country level analysis of the market with respect to the current market size and future prospective • To provide country level analysis of the market for segments by type, by application, by end users and its sub-segments • To provide overview of key players and their strategic profiling in the market, comprehensively analyzing their core competencies, and drawing a competitive landscape for the market • To track and analyze competitive developments such as joint ventures, strategic alliances, mergers and acquisitions, new product developments, and research and developments in the global Radiotherapy market. Intended Audience • Radiotherapy Device manufacturers • Radiotherapy Device Suppliers • Pharmaceutical companies • Research and Development (R&D) Companies • Medical Research Laboratories Global Radiotherapy market has been segmented on the basis of types which comprises of external beam radiation therapy, internal radiation therapy, systemic radiation therapy and others and others. On the basis of end users which consists of hospitals, clinics, research facilities and others. On the basis of application which consists of prostate cancer, breast cancer, spine cancer, penile cancer, esophageal cancer, vulvar cancer and others Some of the key players in this market are: • Varian Medical Systems, Inc (US) • GE Healthcare (UK) • AXREM Limited (UK) • GenesisCare (Australia) • Elekta AB (pub) (Sweden) • Accuray Incorporated (US) • Nordion (Canada) Inc, • IsoRay Medical, Inc (US) • Raysearch Laboratories (Sweden) For more information, please visit https://www.marketresearchfuture.com/reports/radiotherapy-market


News Article | February 26, 2017
Site: www.PR.com

Radiopharmaceuticals Market to Grow at a CAGR of 5.9% by 2026 Future Market Insights has announced the addition of the “Radiopharmaceuticals Market: Global Industry Analysis and Opportunity Assessment 2016-2026" report to their offering. Valley Cottage, NY, February 26, 2017 --( Increasing significance of radiotracers in therapeutic care of cancer and cardiovascular diseases has also impacted the growth in demand for radiopharmaceuticals. In a recent report published by Future Market Insights, the global radiopharmaceuticals revenues in 2016 reached an estimated US$ 4,800 million value, and are anticipated to close in on US$ 8,500 million by the end of 2026. In terms of revenue, the global radiopharmaceuticals market is projected to soar steadily at 5.9% CAGR. Future Market Insights predicts that shorter half-life of radiopharmaceuticals, and lack of specified guidelines for their use in commercial-scale drug production will restrict the market from growing at higher rate. In the years to come, ageing research reactors from all corners of the world will be closed, which will significantly bring down global production of radiopharmaceuticals. With respect to sourcing these radiopharmaceuticals, the report predicts that nuclear reactors have accounted for more than 60% of global market revenues till date. Shutting down these reactors, however, has propelled the installation of cyclotrons, which are also a feasible source for radioisotopes. Hence, sales of radiopharmaceuticals derived from cyclotrons will continue to increase, amassing more than US$ 6,500 million by the end of 2026. Request For Sample@ http://www.futuremarketinsights.com/reports/sample/rep-gb-1992 Surging Demand for Technetium-99 Radioisotope Production of radiopharmaceuticals can be classified into several key radioisotopes, the prominent ones include, fluorine-18, leutetium-177, gallium-68, gallium-67 and technetium-99. In 2016, sales of radiopharmaceuticals constituting technetium-99 amassed revenues worth over US$ 2,200 million, globally. By the end of 2026, fluorine-18 radioisotope will continue to account for 16% of global radiopharmaceuticals revenues. On the other hand, global radiopharmaceutical revenues accounted by leutetium-177, gallium-68 and gallium-67, respectively, will soar at more than 6% CAGR through 2026. North America – Dominant Region for Sales of Radiopharmaceuticals Access to advanced medical facilities, highly-trained professionals and lucrative healthcare expenditure adds up to make North America the most dominant region in global radiopharmaceuticals market. North America’s radiopharmaceuticals revenues will grow at more than 6% CAGR, accounting for nearly 50% of global revenues by the end of 2026. Companies such as Positron Corporation, GE Healthcare, Mallinckrodt plc, Lantheus Holdings, Inc., and Nordion, Inc., are observed to be leading players in global radiopharmaceuticals market, and are all based across North America. Send An Enquiry@ http://www.futuremarketinsights.com/askus/rep-gb-1992 Siemens Healthineers is slated to remain the most dominant company in the global radiopharmaceuticals market, accounting for over 40% of global revenues. Due to participation of Siemens and companies such as Advanced Accelerator Applications (France), Bayer AG (Germany), IBA Radiopharma Solutions (Belgium) and Eckert & Zeigler (Germany), Western Europe’s radiopharmaceuticals market is also expected to expand progressively and close in on US$ 1,600 million valuation by the end of 2026. Radiopharmaceuticals – Scope for Application & End-use Favourable growth opportunities for radiopharmaceutical manufacturers from around the world are sited in therapeutic applications such as oncology, cardiology, neuroendocrinology, and neurology, among others. In 2017 and beyond, consumption of radiopharmaceuticals for oncological procedures will gain traction, registering revenue growth at 6% CAGR. On the other hand, radiopharmaceuticals consumed by neurological studies & treatment procedures will surge at the highest rate, surpassing US$ 700 million valuation by 2026-end. Another key insight offered in the report suggests that radiopharmaceuticals used by diagnostic imaging centres will increase over the forecast period. Nevertheless, every second radiopharmaceutical product manufactured in the world will be used by hospitals. Browse Full Report@ http://www.futuremarketinsights.com/reports/radiopharmaceuticals-market Valley Cottage, NY, February 26, 2017 --( PR.com )-- Presence of radiopharmaceuticals in cancer medications has increased as research institutes have derived ways in which radioisotopes can impede the maturation of malignant tumour, cells and tissues.Increasing significance of radiotracers in therapeutic care of cancer and cardiovascular diseases has also impacted the growth in demand for radiopharmaceuticals.In a recent report published by Future Market Insights, the global radiopharmaceuticals revenues in 2016 reached an estimated US$ 4,800 million value, and are anticipated to close in on US$ 8,500 million by the end of 2026. In terms of revenue, the global radiopharmaceuticals market is projected to soar steadily at 5.9% CAGR.Future Market Insights predicts that shorter half-life of radiopharmaceuticals, and lack of specified guidelines for their use in commercial-scale drug production will restrict the market from growing at higher rate. In the years to come, ageing research reactors from all corners of the world will be closed, which will significantly bring down global production of radiopharmaceuticals. With respect to sourcing these radiopharmaceuticals, the report predicts that nuclear reactors have accounted for more than 60% of global market revenues till date. Shutting down these reactors, however, has propelled the installation of cyclotrons, which are also a feasible source for radioisotopes. Hence, sales of radiopharmaceuticals derived from cyclotrons will continue to increase, amassing more than US$ 6,500 million by the end of 2026.Request For Sample@ http://www.futuremarketinsights.com/reports/sample/rep-gb-1992Surging Demand for Technetium-99 RadioisotopeProduction of radiopharmaceuticals can be classified into several key radioisotopes, the prominent ones include, fluorine-18, leutetium-177, gallium-68, gallium-67 and technetium-99. In 2016, sales of radiopharmaceuticals constituting technetium-99 amassed revenues worth over US$ 2,200 million, globally. By the end of 2026, fluorine-18 radioisotope will continue to account for 16% of global radiopharmaceuticals revenues. On the other hand, global radiopharmaceutical revenues accounted by leutetium-177, gallium-68 and gallium-67, respectively, will soar at more than 6% CAGR through 2026.North America – Dominant Region for Sales of RadiopharmaceuticalsAccess to advanced medical facilities, highly-trained professionals and lucrative healthcare expenditure adds up to make North America the most dominant region in global radiopharmaceuticals market. North America’s radiopharmaceuticals revenues will grow at more than 6% CAGR, accounting for nearly 50% of global revenues by the end of 2026. Companies such as Positron Corporation, GE Healthcare, Mallinckrodt plc, Lantheus Holdings, Inc., and Nordion, Inc., are observed to be leading players in global radiopharmaceuticals market, and are all based across North America.Send An Enquiry@ http://www.futuremarketinsights.com/askus/rep-gb-1992Siemens Healthineers is slated to remain the most dominant company in the global radiopharmaceuticals market, accounting for over 40% of global revenues. Due to participation of Siemens and companies such as Advanced Accelerator Applications (France), Bayer AG (Germany), IBA Radiopharma Solutions (Belgium) and Eckert & Zeigler (Germany), Western Europe’s radiopharmaceuticals market is also expected to expand progressively and close in on US$ 1,600 million valuation by the end of 2026.Radiopharmaceuticals – Scope for Application & End-useFavourable growth opportunities for radiopharmaceutical manufacturers from around the world are sited in therapeutic applications such as oncology, cardiology, neuroendocrinology, and neurology, among others.In 2017 and beyond, consumption of radiopharmaceuticals for oncological procedures will gain traction, registering revenue growth at 6% CAGR.On the other hand, radiopharmaceuticals consumed by neurological studies & treatment procedures will surge at the highest rate, surpassing US$ 700 million valuation by 2026-end.Another key insight offered in the report suggests that radiopharmaceuticals used by diagnostic imaging centres will increase over the forecast period.Nevertheless, every second radiopharmaceutical product manufactured in the world will be used by hospitals.Browse Full Report@ http://www.futuremarketinsights.com/reports/radiopharmaceuticals-market Click here to view the list of recent Press Releases from Future Market Insights


NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Engaged Capital, LLC, an investment firm specializing in enhancing the value of small and mid-cap North American equities, today sent a letter to the Board of Directors (the “Board”) of Rent-A-Center, Inc. (“RCII”) (NASDAQ:RCII) formally nominating five highly qualified candidates for election to the Board at the Company’s upcoming 2017 Annual Meeting of Stockholders. Glenn W. Welling, Managing Member of Engaged Capital, LLC commented, “It is time for change at RCII. The current Board has presided over years of declining operating performance, deteriorating financial results, and a decimation of shareholder value. Despite years of underperformance, these same directors refuse to act with a sense of urgency to explore all alternatives to create value for the owners of the Company. As one of the Company’s largest shareholders, we felt we had no choice but to present shareholders with an alternative slate of directors – directors who can help stabilize the business while also evaluating all strategic options available to the Company. We are pleased that we were able to attract two of the most experienced operators in the industry to our slate: Mitch Fadel, the former President and COO of RCII and Ken Butler, the former COO of AAN, both of whom are highly qualified to replace Mark Speese, RCII’s Chairman, interim CEO and co-founder, who is up for election at this year's meeting. Both have the capabilities and hands-on experience that is sorely missing in RCII’s boardroom today. In addition, Carol McFate, Jeff Brown, and Chris Hetrick bring decades of financial and transaction experience to the Board that is paramount to assessing and taking action on the highest value option for the Company’s future. We believe it is time shareholders have directors who exhibit an understanding that their job is to act as the fiduciaries of all the Company’s shareholders and not just those shares represented in the boardroom.” The full text of the letter follows: Engaged Capital, LLC (together with its affiliates, “Engaged Capital”) has a 12.9% economic interest in Rent-A-Center, Inc. (“RCII” or the “Company”), making us one of the Company’s largest shareholders. As we have expressed numerous times, we believe the RCII Board of Directors (the “Board”) should immediately hire a financial advisor and initiate a strategic alternatives process to evaluate a sale of the entire Company before attempting to pursue a risky public turnaround strategy. The Company’s over 75% decline in share price from its value above $35 a little over two years ago is a stark reminder of the need to benchmark the risk-adjusted alternatives available to the Company. As we highlighted in our December 7, 2016 letter, we believe the Company could command a significant equity premium given the capital structure of the business. For example, based on yesterday’s closing price of $8.40, an acquisition price of $16 per share would represent a 90% premium for shareholders yet only a 38% premium to the Company’s enterprise value. Based on our industry research, we are confident there are numerous parties, both strategic and financial, that would have serious interest in acquiring the Company. Given the history of shareholder value destruction, poor operational execution, weak corporate governance and reactive management change, stubbornly committing to a standalone strategy when other options remain unexplored is simply unacceptable. While we appreciate the open dialogue we have had to date with the Board, we are extremely disappointed by the Company’s apparent refusal to address our concerns. We believe the recent 100,000 share open market purchase by Mark Speese, RCII’s Chairman, interim CEO and co-founder, signals that the Board is unlikely to proactively commence a strategic alternatives process in the near future. As a consequence of this inaction, we have lost confidence in the willingness of the Board to fulfill its fiduciary duty and independently identify the optimal risk-adjusted strategy to restore value to RCII shareholders. Our interactions with the Board thus far suggest its behavior as a whole may reflect a personal loyalty to Mr. Speese, who owns only 2.3% of the Company, at the expense of RCII shareholders. This is particularly concerning because we believe Mr. Speese has a significant conflict of interest that could prevent RCII from maximizing value for its shareholders. By pursuing a risky turnaround strategy that allows him to retain control of the Company he co-founded and to maintain his leadership position, Mr. Speese clearly benefits in ways that shareholders, whose primary interest is the Company’s value, do not benefit. Thus, it is imperative for the Board to not let the personal interests of one director stand in the way of value creation. As we see no evidence that the incumbent Board is willing to prioritize the interest of shareholders, we believe the Board must be reconstituted with new directors who will maintain an unquestionable allegiance to the true owners of the Company – the shareholders. Furthermore, we are extremely concerned that Mr. Speese, under the cover provided by a group of long-tenured and apparently conflicted incumbent directors, may materially harm shareholders if he acts to ensure his continued control of the Company at any cost. These actions include, but are not limited to: 1) Failing to respond to incoming communications from parties expressing an interest in acquiring the Company. It is our understanding that Mr. Speese may be employing this strategy so that he can either legitimately tell the Board he has not received meaningful approaches from interested parties or to limit his interactions to parties that are in his personal best interest. 2) Failing to inform all members of the Board of such inbound communications. 3) Restructuring the Company’s debt in a way that transfers value from equity holders to debt holders, effectively acting as an implicit poison pill (e.g. onerous prepayment penalties) for would-be acquirers. Mr. Speese is having discussions with lenders on refinancing alternatives which we are concerned could make RCII less valuable to an acquirer or make an acquisition of the Company more difficult. 4) Selling a piece of the Company while refusing to evaluate a sale of the entire Company, ultimately damaging the value of the remaining business. 5) Diluting current shareholders by placing equity or convertible debt with a “friendly” party to protect the status quo. 6) Negotiating a sale of the entire Company to a “friendly” party as opposed to running a full and fair process. 7) Delaying a formal consideration of strategic alternatives to provide interim management more time to operate the business, which, despite their best efforts, and based upon recent performance, could result in a continued worsening of operational performance and a further decline in equity value. We are hereby putting each and every director on notice. We will use any and all resources at our disposal to ensure that the approximately 98% of shares outstanding not owned by Mr. Speese are protected from further value destruction. More specifically, we call on RCII’s six independent directors (Michael J. Gade, Rishi Garg, Jeffrey Jackson, J.V. Lentell, Leonard H. Roberts and Stephen L. Pepper) to act objectively in these deliberations and to hold Mr. Speese accountable. You are being closely watched by us and the rest of RCII’s shareholder base. To be clear, we intend to hold each of you personally liable to the fullest extent permitted by law should you continue down a value destructive path and fail to act in the best interests of the Company’s shareholders. We believe that if you choose to do what is right for the Company’s shareholders, as is your duty, the potential exists to create a significant amount of shareholder value by capturing a large percentage of the “fixed” value of RCII in a sale of the Company. Given our interactions with the Company thus far, and the concerns highlighted above in this letter, we feel we have been left with no choice but to seek significant Board change. Given that five of seven incumbent directors have served on the Board for over ten years and two of such directors (including Mr. Speese) have served on the Board for over twenty years, we believe this Board is stale and needs to be refreshed with new directors. We are formally providing the Board notice of our nomination of five highly qualified candidates for election to the Board at the Company’s upcoming 2017 Annual Meeting of Stockholders; provided, however, that we intend to withdraw two of our nominees to the extent that only three seats remain up for election at the meeting. We believe these individuals possess the financial, operational and strategic acumen the Board urgently needs. Our nominees are: Mitchell E. Fadel is currently self-employed after most recently serving as President – U.S. Pawn for EZCORP, Inc. (NASDAQ:EZPW), a leading provider of pawn loans in the United States and Mexico, from September 2015 to December 2016. Prior to that, Mr. Fadel served as RCII’s President (beginning in July 2000) and Chief Operating Officer (beginning in December 2002) each until August 2015, where he also served as a director from December 2000 to November 2013. From 1992 until 2000, Mr. Fadel served as President and Chief Executive Officer of RCII’s subsidiary ColorTyme, Inc., the largest all franchise rent-to-own brand in the country. Mr. Fadel’s professional experience with RCII also includes previously serving as a Regional Director and a District Manager. William K. (Ken) Butler has served as the President, Chief Executive Officer and a director of ATL Leasing Inc., where he manages over 70 Buddy’s Home Furnishings rent-to-own stores in the Southeast, since September 2015. He has also served as President and Chief Executive Officer of Pro Carts, Inc. (d/b/a All Pro Carts), a family owned and operated golf cart sales, service and rental business, since September 2013. Prior to that, Mr. Butler held various leadership positions with Aaron’s, Inc. (NYSE:AAN) (“Aaron’s”), a leading omnichannel provider of lease-purchase solutions, from 1974 to May 2013, where he also served as a director from 2000 until May 2013. Mr. Butler’s most recent executive positions with Aaron’s include serving as its Chief Operating Officer from 2008 to May 2013 and President of its Sales & Lease Ownership Division from 1995 to 2008, a division he served as Vice President of from 1986 to 1995. Mr. Butler previously served as a director of The McPherson Family Trust (d/b/a RE/MAX of Kentucky/Tennessee, Inc., RE/MAX of Georgia, Inc. and RE/MAX of Southern Ohio, Inc.) from 2002 until its sale in December 2016. Mr. Butler was the 2012 recipient of the Ernie Talley Lifetime Achievement Award presented by the Association of Progressive Rental Organizations (APRO), the rent-to-own industry trade group. Carol A. McFate has served as the Chief Investment Officer of Xerox Corporation (NYSE:XRX), a multinational document provider of multifunction document management systems and services, where she manages retirement investment assets for North American and U.K. plans, since 2006. Previously, Ms. McFate served as Executive Vice President & Global Treasurer for XL Global Services, Inc., a US-based subsidiary of XL Capital, Ltd. (NYSE:XLC), a leading Bermuda-based global insurance and reinsurance company, from 2003 to 2006. From 1994 to 2003, Ms. McFate held various positions with American International Group Inc. (NYSE:AIG), an American multinational property & casualty, life insurance, and financial services provider, including Vice President & Treasurer from 1998-2002. From 1988 to 1994, Ms. McFate held various positions with The Prudential Insurance Company of America (NYSE:PRU), an American Fortune Global 500 and Fortune 500 company whose subsidiaries provide insurance, investment management, and other financial products and services to both retail and institutional customers throughout the United States and in over 30 other countries, including Senior Vice President, Financial Restructuring Group, Senior Vice President, Prudential Capital Group and Vice President, Corporate Finance Group. Ms. McFate has been recognized throughout her career for her service, including receiving a Corporate Plan Sponsor Industry Innovation Award from Chief Investment Officer Magazine in 2012 and Chief Investment Officer Power 100 from Chief Investment Officer Magazine from 2011 to 2016. Ms. McFate has also been honored by Institutional Investor, winning two awards in 2014: the Investor Intelligence Network Thought Leadership Award and the Small Corporate Plan Sponsor Award. Jeffrey J. Brown is the Chief Executive Officer and founding member of Brown Equity Partners, LLC (“BEP”), which provides capital to management teams and companies needing equity capital. Prior to founding BEP in 2007, Mr. Brown served as a founding partner and primary deal originator of the venture capital and private equity firm Forrest Binkley & Brown (“FBB”) from 1993 to 2007. In his 30 years in the investment business, Mr. Brown has been on over 40 boards of directors, including service on 8 public companies. Since June 2015, Mr. Brown has served as the Lead Director of Medifast, Inc. (NYSE:MED), a nutrition and weight loss company, where he also serves as a member of each of the Audit and Mergers & Acquisitions Committees. From April 2016 until the completion of its sale in September 2016, Mr. Brown served as a director of Outerwall Inc. (formerly NASDAQ:OUTR), a provider of retail products and services to consumers via self-service interactive kiosks. From February 2014 until May 2016, Mr. Brown served as a director of RCS Capital Corporation (n/k/a Aretec Group, Inc.), an investment firm. From 2011 until 2015, Mr. Brown served as a director of Midatech Pharma PLC (LSE:MTPH), a nano-medicine company. From 2012 until 2014, Mr. Brown served as a director of Nordion, Inc. (NYSE:NDZ), a health science company. From 2009 until 2011, Mr. Brown served as a director of Steadfast Income REIT, Inc., a real estate investment trust. In the course of his career, Mr. Brown has also worked at Hughes Aircraft Company, Morgan Stanley & Company, Security Pacific Capital Corporation and Bank of America Corporation. Christopher B. Hetrick has been the Director of Research at Engaged Capital, a California based investment firm and registered advisor with the U.S. Securities and Exchange Commission focused on investing in small and mid-cap North American equities, since September 2012. Prior to joining Engaged Capital, Mr. Hetrick worked at Relational Investors LLC ("Relational"), a $6 billion activist equity fund, from January 2002 to August 2012. Mr. Hetrick began his career with Relational as an associate analyst. He eventually became the firm's senior consumer analyst overseeing over $1 billion in consumer sector investments. Prior to his work heading up the consumer research team, Mr. Hetrick was a generalist covering major investments in the technology, financial, automotive and food sectors. As we have discussed with you, it is always our intention to work collaboratively with the boards and management teams of our portfolio companies and RCII is no exception. Rather than wasting management’s time and shareholders’ capital on a campaign against our highly qualified nominees, let us work together to bring new perspectives into the boardroom and agree on a path that will create value for all shareholders. Engaged Capital, LLC (“Engaged Capital”) was established in 2012 by a group of professionals with significant experience in activist investing in North America and was seeded by Grosvenor Capital Management, L.P., one of the oldest and largest global alternative investment managers. Engaged Capital is a limited liability company owned by its principals and formed to create long-term shareholder value by bringing an owner’s perspective to the managements and boards of undervalued public companies. Engaged Capital’s efforts and resources are dedicated to a single investment style, “Constructive Activism” with a focus on delivering superior, long-term, risk-adjusted returns for investors. Engaged Capital is based in Newport Beach, California. CERTAIN INFORMATION CONCERNING THE PARTICIPANTS Engaged Capital, LLC (“Engaged Capital”), together with the other participants named herein, intends to file a preliminary proxy statement and accompanying proxy card with the Securities and Exchange Commission (“SEC”) to be used to solicit votes for the election of its slate of highly-qualified director nominees at the 2017 annual meeting of stockholders of Rent-A-Center, Inc., a Delaware corporation (the “Company”). ENGAGED CAPITAL STRONGLY ADVISES ALL STOCKHOLDERS OF THE COMPANY TO READ THE PROXY STATEMENT AND OTHER PROXY MATERIALS AS THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION. SUCH PROXY MATERIALS WILL BE AVAILABLE AT NO CHARGE ON THE SEC’S WEB SITE AT HTTP://WWW.SEC.GOV. IN ADDITION, THE PARTICIPANTS IN THIS PROXY SOLICITATION WILL PROVIDE COPIES OF THE PROXY STATEMENT WITHOUT CHARGE, WHEN AVAILABLE, UPON REQUEST. REQUESTS FOR COPIES SHOULD BE DIRECTED TO THE PARTICIPANTS’ PROXY SOLICITOR. The participants in the proxy solicitation are Engaged Capital Flagship Master Fund, LP (“Engaged Capital Flagship Master”), Engaged Capital Co-Invest V, LP (“Engaged Capital Co-Invest V”), Engaged Capital Flagship Fund, LP (“Engaged Capital Fund”), Engaged Capital Flagship Fund, Ltd. (“Engaged Capital Offshore”), Engaged Capital, Engaged Capital Holdings, LLC (“Engaged Holdings”), Glenn W. Welling, Jeffrey J. Brown, William K. Butler, Mitchell E. Fadel, Christopher B. Hetrick and Carol A. McFate. As of the date hereof, Engaged Capital Flagship Master beneficially owned 2,324,944 shares of common stock, $0.01 par value per share (“Common Stock”). As of the date hereof, Engaged Capital Co-Invest V beneficially owned 2,703,611 shares of Common Stock. As of the date hereof, 259,821 shares of Common Stock were held in an account managed by Engaged Capital (the “Engaged Capital Account”). Each of Engaged Capital Fund and Engaged Capital Offshore, as feeder funds of Engaged Capital Flagship Master, may be deemed to beneficially own the 2,324,944 shares of Common Stock owned by Engaged Capital Flagship Master. Engaged Capital, as the general partner and investment adviser of Engaged Capital Flagship Master and Engaged Capital Co-Invest V and the investment adviser of the Engaged Capital Account, may be deemed to beneficially own the 5,288,376 shares of Common Stock owned in the aggregate by Engaged Capital Flagship Master and Engaged Capital Co-Invest V and held in the Engaged Capital Account. Engaged Holdings, as the managing member of Engaged Capital, may be deemed to beneficially own the 5,288,376 shares of Common Stock owned in the aggregate by Engaged Capital Flagship Master and Engaged Capital Co-Invest V and held in the Engaged Capital Account. Mr. Welling, as the Founder and Chief Investment Officer of Engaged Capital and sole member of Engaged Holdings, may be deemed to beneficially own the 5,288,376 shares of Common Stock owned in the aggregate by Engaged Capital Flagship Master and Engaged Capital Co-Invest V and held in the Engaged Capital Account. As of the date hereof, Messrs. Brown, Butler, Fadel and Hetrick and Ms. McFate did not beneficially own any shares of Common Stock.


OTTAWA, Dec. 7, 2016 /PRNewswire/ - Nordion, a standalone business of Sterigenics International, in partnership with General Atomics (GA), welcome today's award by the United States Department of Energy's (DOE) National Nuclear Security Administration (NNSA) of the Phase II cooperative...


OTTAWA, Ontario, Dec. 7, 2016 /PRNewswire/ -- Nordion, a standalone business of Sterigenics International, in partnership with General Atomics (GA), welcome today's award by the United States Department of Energy's (DOE) National Nuclear Security Administration (NNSA) of the Phase II...


OTTAWA, 7 de dezembro de 2016 /PRNewswire/ -- A Nordion, empresa autônoma da Sterigenics International, em parceria com a General Atomics (GA), receberam hoje da Administração Nacional de Segurança Nuclear (NNSA -- National Nuclear Security Administration) do Departamento de Energia (DOE)...


News Article | December 2, 2016
Site: www.newsmaker.com.au

According to Stratistics MRC, the Global Radiotherapy Market is accounted for $6.5 billion in 2015 and is expected to reach $10.2 billion by 2022 growing at a CAGR of 6.6% during the forecast period. Rising number of cancer patients, technological advancements and increasing aging population are some of the key factors fueling the market growth. However, lack of sufficient infrastructure and healthcare costs are expected to hinder the market. Technologies such as External beam radiotherapy and internal beam radiotherapy are anticipated to witness highest growth owing to increased pool of cancer patients. North America commanded the largest market share as it is constantly inclined to the newer technologies when compared to slow-moving markets such as Europe. Rising incidence of cancer and unmet healthcare needs in APAC provides ample of opportunities for the players in the market over the foreseeable future. Some of the key players in the market include Siemens Healthcare, GE Healthcare, Nordion, Inc., IBA Group, Angiodynamics Inc, Ion Beam Applications SA, Protom International Inc, IsoRay Medical, Inc., Coviden Plc, Varian Medical Systems Inc, Accuray Inc, Mevion Medical Systems, Inc, C.R. BARD Inc, CIVCO Medical Solutions, Mitsubishi Electric Corporation, Brainlab AG, RaySearch Laboratories AB, Elekta AB and Nanobiotix. Regions Covered: • North America o US o Canada o Mexico • Europe o Germany o France o Italy o UK  o Spain o Rest of Europe       • Asia Pacific o Japan        o China        o India        o Australia        o New Zealand       o Rest of Asia Pacific • Rest of the World o Middle East o Brazil       o Argentina        o South Africa o Egypt What our report offers: - Market share assessments for the regional and country level segments - Market share analysis of the top industry players - Strategic recommendations for the new entrants - Market forecasts for a minimum of 7 years of all the mentioned segments, sub segments and the regional markets - Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations) - Strategic recommendations in key business segments based on the market estimations - Competitive landscaping mapping the key common trends - Company profiling with detailed strategies, financials, and recent developments - Supply chain trends mapping the latest technological advancements

Loading Nordion collaborators
Loading Nordion collaborators